{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:52:23Z","timestamp":1789807943858,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.sapharm.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:13:06Z","timestamp":1770970386000},"page":"646-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increasing the use of long-acting injectable behavioral health medications in the community - A pharmacist-psychiatrist collaborative model"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2173-6794","authenticated-orcid":false,"given":"Jerry R.","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Reinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Chiyaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Viracola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2026.02.004_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.808002","article-title":"Long-acting injectable antipsychotic treatment in schizophrenia and co-occurring substance use disorders: a systematic review","volume":"12","author":"Coles","year":"2021","journal-title":"Front Psychiatr"},{"issue":"4","key":"10.1016\/j.sapharm.2026.02.004_bib2","article-title":"The use of long-acting injectable antipsychotics (LAI) in the serious mental illness (SMI) patients enrolled in an assertive community treatment (ACT) program","volume":"13","author":"Yee","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.sapharm.2026.02.004_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41380-024-02694-3","article-title":"All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis","volume":"30","author":"Aymerich","year":"2025","journal-title":"Mol Psychiatr"},{"issue":"2","key":"10.1016\/j.sapharm.2026.02.004_bib4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s12325-024-03075-6","article-title":"Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US Medicare patients with schizophrenia","volume":"42","author":"Li","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.sapharm.2026.02.004_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: from development to implementation","volume":"10","author":"Ling","year":"2019","journal-title":"Subst Abuse Rehabil"},{"issue":"6","key":"10.1016\/j.sapharm.2026.02.004_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.sapharm.2026.02.004_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2147\/NDT.S473492","article-title":"Impact of demographics and insurance coverage on schizophrenia treatment and healthcare resource utilization within an integrated healthcare system","volume":"20","author":"Seo","year":"2024","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.sapharm.2026.02.004_bib8","series-title":"Improving Utilization of long-acting Medications: Toward Standardized Measures","year":"2025"},{"issue":"3","key":"10.1016\/j.sapharm.2026.02.004_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11414-013-9329-z","article-title":"Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia","volume":"40","author":"Lin","year":"2013","journal-title":"J Behav Health Serv Res"},{"issue":"2","key":"10.1016\/j.sapharm.2026.02.004_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/pharmacy11020045","article-title":"Pharmacist administration of long-acting injectable antipsychotics to community-dwelling patients: a scoping review","volume":"11","author":"Murphy","year":"2023","journal-title":"Pharmacy"},{"key":"10.1016\/j.sapharm.2026.02.004_bib11","article-title":"Community pharmacists' attitudes toward the administration of long-acting injectable antipsychotic therapies","volume":"56","author":"Gupta","year":"2016","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.sapharm.2026.02.004_bib12","first-page":"1","author":"Roesler","year":"2025"},{"issue":"1","key":"10.1016\/j.sapharm.2026.02.004_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/104012371402600104","article-title":"Barriers to utilizing long-acting injectable antipsychotic medications","volume":"26","author":"Getzen","year":"2014","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"key":"10.1016\/j.sapharm.2026.02.004_bib14","article-title":"Pharmacist administration of long-acting injectable antipsychotics","volume":"3","year":"2024","journal-title":"NASPA June"},{"issue":"6","key":"10.1016\/j.sapharm.2026.02.004_bib15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc"},{"issue":"12","key":"10.1016\/j.sapharm.2026.02.004_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ajhp\/zxab171","article-title":"White bagging a growing concern for health systems","volume":"78","author":"Traynor","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2026.02.004_bib17","series-title":"Health insurer specialty pharmacy policies threaten patient quality of care","first-page":"1","year":"2021"},{"key":"10.1016\/j.sapharm.2026.02.004_bib18","unstructured":"Shedding Light on NADAC: How Pricing Power Influences Pharmacy Reimbursement. The Ohio State University College of Pharmacy. Accessed December 23, 2025. https:\/\/pharmacy.osu.edu\/news\/shedding-light-nadac-how-pricing-power-influences-pharmacy-reimbursement."},{"key":"10.1016\/j.sapharm.2026.02.004_bib19","series-title":"Administration of Long Acting Injectable Medications","year":"2021"},{"issue":"3","key":"10.1016\/j.sapharm.2026.02.004_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.japh.2022.08.006","article-title":"Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications","volume":"63","author":"Black","year":"2023","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"4","key":"10.1016\/j.sapharm.2026.02.004_bib22","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.japh.2022.01.016","article-title":"Evaluation of patient satisfaction and perceptions of a long-acting injectable antipsychotic medication administration service in a community-based pharmacy during the COVID-19 pandemic","volume":"62","author":"Mascari","year":"2022","journal-title":"J Am Pharm Assoc"},{"issue":"9","key":"10.1016\/j.sapharm.2026.02.004_bib23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.sapharm.2024.06.006","article-title":"A pharmacist clinician model as part of a collaborative clinical workforce: a philosophical critique","volume":"20","author":"Rushworth","year":"2024","journal-title":"Res Soc Adm Pharm RSAP"},{"issue":"7","key":"10.1016\/j.sapharm.2026.02.004_bib24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.sapharm.2020.10.004","article-title":"Community pharmacy-based injectable naltrexone service delivery models and best practices","volume":"17","author":"Ford","year":"2021","journal-title":"Res Soc Adm Pharm"},{"issue":"7","key":"10.1016\/j.sapharm.2026.02.004_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.healthpol.2017.04.013","article-title":"Time-driven activity-based costing in health care: a systematic review of the literature","volume":"121","author":"Keel","year":"2017","journal-title":"Health Policy"},{"key":"10.1016\/j.sapharm.2026.02.004_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1276373","article-title":"Micro-costing analysis of suspected lower respiratory tract infection care in a French emergency department","volume":"11","author":"Wilm\u00e9","year":"2023","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.sapharm.2026.02.004_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.sapharm.2015.08.004","article-title":"Pharmaceutical services cost analysis using time-driven activity-based costing: a contribution to improve community pharmacies' management","volume":"12","author":"Greg\u00f3rio","year":"2016","journal-title":"Res Soc Adm Pharm RSAP"},{"key":"10.1016\/j.sapharm.2026.02.004_bib28","author":"Shoemaker-Hunt","year":"2020"},{"key":"10.1016\/j.sapharm.2026.02.004_bib29","unstructured":"Healthcare occupations. Bureau Labor Stat. Accessed August 5, 2025. https:\/\/www.bls.gov\/ooh\/healthcare\/."},{"key":"10.1016\/j.sapharm.2026.02.004_bib30","unstructured":"Pharmacy technician salary in United States. Accessed August 5, 2025. https:\/\/www.indeed.com\/career\/pharmacy-technician\/salaries?from=top_sb."},{"key":"10.1016\/j.sapharm.2026.02.004_bib31","series-title":"The pharmacists\u2019 patient care process","first-page":"1","year":"2025"},{"issue":"4","key":"10.1016\/j.sapharm.2026.02.004_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JCP.0000000000001225","article-title":"Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"40","author":"Lindenmayer","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.sapharm.2026.02.004_bib33","first-page":"474","article-title":"Savings on high-cost drugs such as atypical long-acting injectable antipsychotics: switching to billing under the pharmacy benefit in outpatient settings","volume":"44","author":"Budovich","year":"2019","journal-title":"P T Peer-Rev J Formul Manag"},{"key":"10.1016\/j.sapharm.2026.02.004_bib34","series-title":"NC Medicaid","article-title":"COVID-19 vaccine and reimbursement guidelines for 2024-2025 for NC medicaid","year":"2024"},{"issue":"4S","key":"10.1016\/j.sapharm.2026.02.004_bib35","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.japh.2018.04.035","article-title":"Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy","volume":"58","author":"Mooney","year":"2018","journal-title":"J Am Pharm Assoc JAPhA"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:05:39Z","timestamp":1777619139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741126000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1551741126000276"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.02.004","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increasing the use of long-acting injectable behavioral health medications in the community - A pharmacist-psychiatrist collaborative model","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}